• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    8/2/22 8:20:04 AM ET
    $AHCO
    $ALLR
    $AVTX
    $EHAB
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHCO alert in real time by email

     

    Gainers

    • Allarity Therapeutics (NASDAQ:ALLR) stock rose 16.4% to $1.42 during Tuesday's pre-market session. The company's market cap stands at $13.1 million.
    • Vaccinex (NASDAQ:VCNX) stock rose 12.91% to $1.15. The company's market cap stands at $49.1 million.
    • Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 12.49% to $4.05. The market value of their outstanding shares is at $38.0 million.
    • Harmony Biosciences (NASDAQ:HRMY) shares moved upwards by 10.25% to $54.28. The market value of their outstanding shares is at $3.2 billion. As per the news, the Q2 earnings report came out today.
    • Sonnet BioTherapeutics (NASDAQ:SONN) shares increased by 9.84% to $0.3. The company's market cap stands at $18.1 million.
    • AdaptHealth (NASDAQ:AHCO) stock increased by 9.5% to $24.42. The market value of their outstanding shares is at $3.2 billion.

    Losers

    • Eliem Therapeutics (NASDAQ:ELYM) stock decreased by 25.3% to $2.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $60.3 million.
    • Syneos Health (NASDAQ:SYNH) shares declined by 13.45% to $68.5. The market value of their outstanding shares is at $7.0 billion. As per the news, the Q2 earnings report came out today.
    • Reviva Pharmaceuticals (NASDAQ:RVPH) shares fell 12.0% to $0.66. The market value of their outstanding shares is at $9.9 million.
    • Enhabit (NYSE:EHAB) shares decreased by 11.02% to $15.99. The market value of their outstanding shares is at $797.8 million. The company's, Q2 earnings came out yesterday.
    • IMAC Holdings (NASDAQ:IMAC) stock declined by 10.89% to $0.9. The company's market cap stands at $23.8 million.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) stock fell 10.24% to $0.94. The company's market cap stands at $10.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHCO
    $ALLR
    $AVTX
    $EHAB

    CompanyDatePrice TargetRatingAnalyst
    Harmony Biosciences Holdings Inc.
    $HRMY
    2/23/2026Buy → Hold
    Deutsche Bank
    Harmony Biosciences Holdings Inc.
    $HRMY
    2/23/2026Buy → Hold
    Truist
    Harmony Biosciences Holdings Inc.
    $HRMY
    2/11/2026$46.00Neutral
    UBS
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Enhabit Inc.
    $EHAB
    1/22/2026$14.00Perform → Outperform
    Oppenheimer
    Enhabit Inc.
    $EHAB
    1/13/2026$12.00Hold → Buy
    TD Cowen
    Enhabit Inc.
    $EHAB
    1/8/2026$12.00Neutral → Buy
    UBS
    Enhabit Inc.
    $EHAB
    1/7/2026$10.50Hold
    Truist
    More analyst ratings

    $AHCO
    $ALLR
    $AVTX
    $EHAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Harmony Biosciences downgraded by Deutsche Bank

    Deutsche Bank downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:47 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences downgraded by Truist

    Truist downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:36 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Harmony Biosciences with a new price target

    UBS resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $46.00

    2/11/26 7:39:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHCO
    $ALLR
    $AVTX
    $EHAB
    SEC Filings

    View All

    Enhabit Inc. filed SEC Form 8-K: Leadership Update

    8-K - Enhabit, Inc. (0001803737) (Filer)

    2/27/26 4:27:47 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    SEC Form DEFA14A filed by Enhabit Inc.

    DEFA14A - Enhabit, Inc. (0001803737) (Filer)

    2/26/26 4:06:39 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    SEC Form 10-K filed by AdaptHealth Corp.

    10-K - AdaptHealth Corp. (0001725255) (Filer)

    2/24/26 5:09:46 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    $ALLR
    $AVTX
    $EHAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    CLO and General Counsel Rew Richard W. Ii bought $44,550 worth of shares (5,000 units at $8.91), increasing direct ownership by 5% to 107,097 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    2/27/26 4:01:18 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Solomon Ryan bought $76,400 worth of shares (10,000 units at $7.64), increasing direct ownership by 5% to 193,468 units (SEC Form 4)

    4 - Enhabit, Inc. (0001803737) (Issuer)

    8/11/25 6:30:04 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    $AHCO
    $ALLR
    $AVTX
    $EHAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    General Counsel and Secretary Black Dylan C covered exercise/tax liability with 11,054 shares and was granted 19,228 shares, increasing direct ownership by 11% to 84,499 units (SEC Form 4)

    4 - Enhabit, Inc. (0001803737) (Issuer)

    3/3/26 5:49:14 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Chief Human Resources Officer Marion Tanya Renee covered exercise/tax liability with 8,944 shares and was granted 14,425 shares, increasing direct ownership by 7% to 89,291 units (SEC Form 4)

    4 - Enhabit, Inc. (0001803737) (Issuer)

    3/3/26 5:48:33 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    $AHCO
    $ALLR
    $AVTX
    $EHAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AdaptHealth Corp. to Participate in Upcoming Investor Conferences

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the following upcoming investor conferences: The J.P. Morgan Global Leveraged Finance Conference, being held in Miami, on Tuesday, March 3, 2026, including a fireside chat at 11:00 a.m. ET. The Leerink Partners Global Healthcare Conference, being held in Miami, on Monday, March 9, 2026, including a fireside chat at 2:20 p.m. ET. Webcast links will be available on the Company's website, www.adapthealth.com under "Investor R

    2/25/26 4:05:00 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

    WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications Potential Best-In-Class Orexin-2 Agonist (BP1.15205) Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026 Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced ear

    2/24/26 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results and Provides 2026 Financial Guidance

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter Business Highlights Set patient census records for Sleep Health, Respiratory Health, and Wellness at Home, and a patient retention record for Diabetes Health. Acquired a leading HME provider in Hawaii, expanding the Company's geographic footprint to its 48th State and establishing operations to support the Company's new key capitated contract. Made signif

    2/24/26 7:00:00 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    $ALLR
    $AVTX
    $EHAB
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

    WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said

    9/22/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

        TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period. Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other

    7/7/25 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHCO
    $ALLR
    $AVTX
    $EHAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

    SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

    11/18/24 4:15:28 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Enhabit Inc.

    SC 13G - Enhabit, Inc. (0001803737) (Subject)

    11/14/24 9:12:39 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHCO
    $ALLR
    $AVTX
    $EHAB
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

    WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications Potential Best-In-Class Orexin-2 Agonist (BP1.15205) Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026 Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced ear

    2/24/26 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results and Provides 2026 Financial Guidance

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter Business Highlights Set patient census records for Sleep Health, Respiratory Health, and Wellness at Home, and a patient retention record for Diabetes Health. Acquired a leading HME provider in Hawaii, expanding the Company's geographic footprint to its 48th State and establishing operations to support the Company's new key capitated contract. Made signif

    2/24/26 7:00:00 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Enhabit to be Acquired by Kinderhook Industries

    Enhabit, Inc. Stockholders to Receive $13.80 per Share in Cash Enhabit, Inc. (NYSE:EHAB), a leading national home health and hospice provider, today announced it has entered into a definitive agreement to be acquired by Kinderhook Industries, LLC ("Kinderhook"), a middle market private equity firm, in an all-cash transaction for a total enterprise value of approximately $1.1 billion. Under the terms of the agreement, Enhabit stockholders will receive $13.80 per share in cash, which represents a premium of approximately 24.4% to the Company's closing stock price on February 20, 2026, the last full trading day prior to the announcement of the transaction, and a 33.8% premium to the Compan

    2/23/26 8:00:00 AM ET
    $EHAB
    Medical/Nursing Services
    Health Care